Research
Postmenopausal estrogen and progestin effects on the serum proteome
-
* Corresponding author: Ross L Prentice rprentic@fhcrc.org
1 Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
2 Department of Pediatrics, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
3 Biomarkers and Personalized Medicine Unit, Eisai Inc., 4 Corporate Drive, Andover, MA 01810, USA
4 WHI Project Office, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, USA
5 Division of Endocrinology, Ohio State University, 198 McCampbell, 1581 Dodd Drive, Columbus, OH 43210, USA
6 Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
7 Research and Development, AstraZeneca LP, 1971 Rockland Road, Wilmington, DE 19803, USA
8 Division of Public Health, Epidemiology & David Geffen School of Medicine, Department of Medicine, Box 951772, Los Angeles, CA 90095, USA
9 Department of Medicine, George Washington University, 2121 Eye St, NW; Washington, DC 20052, USA
Genome Medicine 2009, 1:121 doi:10.1186/gm121
Published: 24 December 2009Additional files
Additional file 1:
Table S1 shows year 1 to baseline log-transformed concentration ratios after estrogen plus progestin (E+P) or estrogen (E-Alone) exposure for all 378 quantified proteins.
Format: XLS Size: 98KB Download file
This file can be viewed with: Microsoft Excel Viewer
